{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:01:39Z","timestamp":1784772099761,"version":"3.55.0"},"reference-count":27,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Issues Mol. Biol.","CIMB"],"abstract":"<jats:p>Background\/Aim: Fibroblast growth factor receptor 4 (FGFR4) is a tyrosine kinase involved in cell growth, proliferation, and angiogenesis. While FGFR1\u20133 are well studied in cancer, FGFR4 remains relatively understudied, and the distribution of its mutations across cancers and patient populations is not well defined. Materials and Methods: A retrospective pan-cancer analysis was performed using the AACR Project GENIE v12 database via cBioPortal. Tumors with somatic FGFR4 mutations were included, excluding copy number alterations and structural variants. Mutations were grouped by hotspot (amino acid 401) and major protein domains. Comparative analyses assessed cancer type distribution, demographics, mutation burden, and co-occurring genomic alterations using chi-square testing with multiple comparison correction. Results: A total of 4565 tumor samples (4283 patients) were analyzed. FGFR4 alterations were observed across diverse malignancies, most commonly non-small cell lung cancer, colorectal cancer, and melanoma. Mutations clustered primarily in the tyrosine kinase and immunoglobulin I-set domains, with no significant variation in distribution across cancer types. Sex was not associated with the mutation group, while race and ethnicity showed significant differences. The FGFR4 hotspot 401 group demonstrated a higher mutation burden, driven by a subset of hypermutated tumors, and showed enrichment for co-occurring alterations in chromatin remodeling, DNA repair, tumor suppressor, and receptor tyrosine kinase genes; however, sensitivity analyses indicated this association was largely attributable to mutation burden rather than a mutation-specific effect. Domain-based mutation groups had lower mutation burdens and fewer co-alterations. Conclusions: FGFR4 alterations occur across a broad range of cancers with consistent domain-level patterns. The hotspot 401 mutation shows a higher mutation burden and co-alteration frequency driven largely by a subset of hypermutated tumors, rather than acting as an isolated driver.<\/jats:p>","DOI":"10.3390\/cimb48070748","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:01:28Z","timestamp":1784768488000},"page":"748","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mutational Landscape of FGFR4 Across Malignancies: A Cross-Cancer Analysis of the AACR Project GENIE Database"],"prefix":"10.3390","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3124-6666","authenticated-orcid":false,"given":"Henna","family":"Ali","sequence":"first","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Gengnagel","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem","family":"Birkholz","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2549-8496","authenticated-orcid":false,"given":"Gowri","family":"Vadmal","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elijah","family":"Torbenson","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6403-502X","authenticated-orcid":false,"given":"Beau","family":"Hsia","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Phoenix, AZ 85012, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abubakar","family":"Tauseef","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter T.","family":"Silberstein","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"},{"name":"Department of Hematology\/Oncology, CHI Henry Lynch Cancer Center, Omaha, NE 68124, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"107590","DOI":"10.1016\/j.pharmthera.2020.107590","article-title":"FGFR4: A promising therapeutic target for breast cancer and other solid tumors","volume":"214","author":"Levine","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Dai, S., Zhou, Z., Chen, Z., Xu, G., and Chen, Y. (2019). Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors. Cells, 8.","DOI":"10.3390\/cells8060614"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s003359900703","article-title":"Genomic structure and complete sequence of the human FGFR4 gene","volume":"9","author":"Kostrzewa","year":"1998","journal-title":"Mamm. Genome"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1021\/acsmedchemlett.9b00601","article-title":"Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma","volume":"11","author":"Liu","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1111\/cas.13759","article-title":"Role of fibroblast growth factor receptor 4 in cancer","volume":"109","author":"Tang","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: A Precision Oncology Knowledge Base","volume":"1","author":"Chakravarty","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nbt.3391","article-title":"Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity","volume":"34","author":"Chang","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic Signaling Pathways in The Cancer Genome Atlas","volume":"173","author":"Mina","year":"2018","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mohammadi, M., and Beenken, A. (2017). FGF-FGFR Signaling in Cancer. Cancer Therapeutic Targets, Springer.","DOI":"10.1007\/978-1-4419-0717-2_19"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/sj.bjc.6603181","article-title":"FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients","volume":"94","author":"Streit","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2016.12.012","article-title":"MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition","volume":"73","author":"Amaral","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","article-title":"Targeting FGFR for cancer therapy","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Pel\u00e1ez-Garc\u00eda, A., Barderas, R., Torres, S., Hern\u00e1ndez-Varas, P., Teixid\u00f3, J., Bonilla, F., De Herreros, A.G., and Casal, J.I. (2013). FGFR4 Role in Epithelial-Mesenchymal Transition and Its Therapeutic Value in Colorectal Cancer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063695"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)","volume":"38","author":"Katoh","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: Genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lang, L., and Teng, Y. (2019). Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies. Cells, 8.","DOI":"10.3390\/cells8010031"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor-tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1093\/bioinformatics\/btx149","article-title":"PathwayMapper: A collaborative visual web editor for cancer pathways and genomic data","volume":"33","author":"Bahceci","year":"2017","journal-title":"Bioinformatics"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Zheng, J., Zhang, W., Li, L., He, Y., Wei, Y., Dang, Y., Nie, S., and Guo, Z. (2022). Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review. Front. Chem., 10.","DOI":"10.3389\/fchem.2022.860985"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41698-023-00351-6","article-title":"Racial and ethnic disparities in a real-world precision oncology data registry","volume":"7","author":"Cheung","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jamaoncol.2016.1854","article-title":"Racial\/Ethnic Disparities in Genomic Sequencing","volume":"2","author":"Spratt","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_25","first-page":"3395","article-title":"Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models","volume":"119","author":"Vi","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102530","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: Treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12929-022-00856-5","article-title":"Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response","volume":"29","author":"Mandal","year":"2022","journal-title":"J. Biomed. Sci."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/7\/748\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:20:15Z","timestamp":1784769615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/7\/748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cimb48070748"],"URL":"https:\/\/doi.org\/10.3390\/cimb48070748","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}